- Home
- MRSN vs PERF Comparison
MRSN vs PERF Comparison
Compare MRSN & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- PERF
- Stock Information
- Founded
- MRSN 2001
- PERF 2015
- Country
- MRSN United States
- PERF Taiwan
- Employees
- MRSN N/A
- PERF N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- PERF Computer Software: Prepackaged Software
- Sector
- MRSN Health Care
- PERF Technology
- Exchange
- MRSN Nasdaq
- PERF Nasdaq
- Market Cap
- MRSN 252.0M
- PERF 266.8M
- IPO Year
- MRSN 2017
- PERF N/A
- Fundamental
- Price
- MRSN $0.62
- PERF $2.59
- Analyst Decision
- MRSN Buy
- PERF Buy
- Analyst Count
- MRSN 6
- PERF 2
- Target Price
- MRSN $6.00
- PERF $4.00
- AVG Volume (30 Days)
- MRSN 7.3M
- PERF 291.7K
- Earning Date
- MRSN 02-26-2025
- PERF 02-26-2025
- Dividend Yield
- MRSN N/A
- PERF N/A
- EPS Growth
- MRSN N/A
- PERF N/A
- EPS
- MRSN N/A
- PERF 0.05
- Revenue
- MRSN $34,837,000.00
- PERF $58,445,000.00
- Revenue This Year
- MRSN N/A
- PERF $15.76
- Revenue Next Year
- MRSN N/A
- PERF $13.32
- P/E Ratio
- MRSN N/A
- PERF $51.03
- Revenue Growth
- MRSN N/A
- PERF 15.84
- 52 Week Low
- MRSN $0.56
- PERF $1.70
- 52 Week High
- MRSN $6.28
- PERF $3.77
- Technical
- Relative Strength Index (RSI)
- MRSN 20.37
- PERF 51.68
- Support Level
- MRSN $0.56
- PERF $2.25
- Resistance Level
- MRSN $1.45
- PERF $3.19
- Average True Range (ATR)
- MRSN 0.14
- PERF 0.42
- MACD
- MRSN -0.06
- PERF -0.03
- Stochastic Oscillator
- MRSN 6.49
- PERF 28.57
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.